Electroconvulsive shock and neurotransmitter receptors: implications for mechanism of action and adverse effects of electroconvulsive therapy
- PMID: 6144329
Electroconvulsive shock and neurotransmitter receptors: implications for mechanism of action and adverse effects of electroconvulsive therapy
Abstract
Neurochemical effects of electroconvulsive shock (ECS) in three neurotransmitter-receptor systems were studied in relation to the mechanism of action and adverse effects of ECT. In the noradrenergic system, chronically administered ECS, along with other effective antidepressant treatments, has been consistently reported to down-regulate beta-adrenergic receptors in rat cerebral cortex. Even when ECS was administered according to an intermittent clinically equivalent schedule, a 21% reduction in cortical 3H-DHA binding to beta-adrenoreceptors could be demonstrated 4 days after the last treatment. However, the role of presynaptic NA events in beta-adrenoreceptor down-regulation by ECS and the antidepressant mechanism of ECT remains to be clarified. Compared to the MAO inhibitor clorgyline, repeated ECS pretreatment induced only a moderate increase in NA release from a rat cortical vesicular preparation and minimally reduced the sensitivity of the preparation to release-inhibition by clonidine. In the dopaminergic system, a clinically equivalent ECS schedule had no direct effect on behavioral or biochemical indices of DA receptor sensitivity. However, the same ECS schedule significantly attenuated haloperidol-induced behaviorally and biochemically measured DA supersensitivity in the same model in which parallel effects had been reported for lithium. The possibility that a "receptor-stabilizing" mechanism may be common to ECT and lithium is considered on the basis of similarities in the clinical profiles of the two treatments. In the cholinergic system, repeated ECS significantly reduced 3H-QNB binding to muscarinic cholinergic receptors in rat cerebral cortex and hippocampus. Concurrently administered ECS also blocked the increase in 3H-QNB binding caused by chronic atropine administration. ECS effects on muscarinic cholinergic receptors may have relevance to the antidepressant mechanism of ECT.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Electroconvulsive Shock and Brain Cholinergic Function: Role of Striatal Muscarinic Receptors.Convuls Ther. 1985;1(3):158-166. Convuls Ther. 1985. PMID: 11940819
-
Brain neurotransmitter receptor binding and nootropic studies on Indian Hypericum perforatum Linn.Phytother Res. 2002 May;16(3):210-6. doi: 10.1002/ptr.1101. Phytother Res. 2002. PMID: 12164263
-
A role of some central neurotransmitter systems in the mechanism of electroconvulsive shock action.Pol J Pharmacol Pharm. 1985 Nov-Dec;37(6):745-52. Pol J Pharmacol Pharm. 1985. PMID: 3008135
-
Magnetic stimulation of the brain in animal depression models responsive to ECS.J ECT. 1998 Sep;14(3):194-205. J ECT. 1998. PMID: 9773358 Review.
-
[Biochemical effects of electroconvulsotherapy].Encephale. 1988 Jul-Aug;14(4):273-81. Encephale. 1988. PMID: 2848680 Review. French.
Cited by
-
Regional neurotransmitter responses after acute and chronic electroconvulsive shock.Psychopharmacology (Berl). 1990;100(1):60-5. doi: 10.1007/BF02245791. Psychopharmacology (Berl). 1990. PMID: 1688661
-
Repeated electroconvulsive shock produces long-lasting increases in messenger RNA expression of corticotropin-releasing hormone and tyrosine hydroxylase in rat brain. Therapeutic implications.J Clin Invest. 1994 Sep;94(3):1263-8. doi: 10.1172/JCI117444. J Clin Invest. 1994. PMID: 7916018 Free PMC article.
-
The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: a retrospective study.Neuropsychiatr Dis Treat. 2014 Jul 3;10:1209-12. doi: 10.2147/NDT.S62490. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 25061306 Free PMC article.
-
Prophylactic cognitive enhancers for improvement of cognitive function in patients undergoing electroconvulsive therapy: A systematic review and meta-analysis.Medicine (Baltimore). 2020 Mar;99(11):e19527. doi: 10.1097/MD.0000000000019527. Medicine (Baltimore). 2020. PMID: 32176105 Free PMC article.
-
Cognitive Impairment and Electroconvulsive Therapy in Geriatric Depression, What Could be the Role of Rivastigmine? A Case Series.Clin Pract. 2015 Sep 28;5(3):780. doi: 10.4081/cp.2015.780. eCollection 2015 Sep 28. Clin Pract. 2015. PMID: 26664715 Free PMC article.